Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: Effect of switching from subcutaneous to intravenous administration

Nephron - Clinical Practice

Volumn 102, Issue 3-4, 2006, Pages

  Raymond, Colette B ^a   Collins, David M ^b   Bernstein, Keevin N ^b,c   Skwarchuk, Dan E ^b   Vercaigne, Lavern M ^b  

^a WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Erythropoietin administration; Intravenous; Subcutaneous

Indexed keywords

ERYTHROPOIETIN ALPHA; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; STATISTICAL ANALYSIS;

ANEMIA; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 33644542445     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089665     Document Type: Article

References (21)

1. Eschbach JW: The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-148.
2. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990;263:825-830.
3. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997;30(suppl 3):S192-S240.
4. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37:S182-S238.
5. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14(suppl 5):1-50.
6. Barrett BJ, Fenton SS, Ferguson B, et al: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Naphrology. J Am Soc Nephrol 1999;10(suppl 13):S292-S296.
7. Kaufman JS, Reda DJ, Fye CL, et al: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-583.
8. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-446.
9. Jacobs C, Horl WH, Macdougall IC, et al: European best practice guidelines 9-13: anaemia management. Nephrol Dial Transplant 2000;15(suppl 4):33-42.
10. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr: Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 2001;37:E36.
11. Casadevall N, Nataf J, Viron B, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
12. Gershon SK, Luksenburg H, Cote TR, Braun MM: Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-1586.
13. Summary of PRCA Case Reports December 31, 2002. Johnson & Johnson, 2002, vol 2003.
14. Casadevall N: Pure red cell aplasia and antierythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003;18(suppl 8):viii37-viii41.
15. Levin A, BB, Wong G, et al: Letter from the Canadian Society of Nephrologists. Canadian Society of Nephrologists, 2002, vol 2003.
16. Parfrey P, Barrett BJ, Levin A, et al: Letter from the Canadian Society of Nephrologists. Vol. 2003: Canadian Society of Nephrologists, 2003.
17. Bovy C, DB, Popovic, A et al: Mode of administration of erythropoietin (rHuEpo) - does it matter? (abstract). Nephrol Dial Transplant 1995;10:1951A-1952A.
18. Jensen JD, Madsen JK, Jensen LW: Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur J Clin Pharmacol 1996;50:171-177.
19. Steffensen G, Aunsholt, NA, Ahlbom, G: Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients. Blood Purif 1992;10:214-247.
20. Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK: Erythropoietin response and route of administration. Clin Nephrol 1994;41:297-302.
21. Virot JS, Janin G, Guillaumie J, et al: Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 1996;28:400-408.